Clinical Trials – Outlook And Trends For 2023
Clinical trials for testing potential drugs, procedures, or devices have evolved over hundreds of years. Scientists use clinical trials on...
Day: February 6, 2023
Sharps Technology Announces Closing of $3.8 Million Private Placement Priced At-the-Market
NEW YORK, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative...
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
Mesa Labs Announces Third Quarter Results
LAKEWOOD, Colo., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing...
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination
MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose...
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent
– The study will evaluate the safety, tolerability and ability of OP-801 to cross the blood brain barrier and selectively...
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
Full end-to-end, GMP manufacturing of OPTI-MHCL solidifies the Company’s plan to address the global demand for MDMA in 2023 and...
By The Bay Health CEO Announces Retirement
Efforts to identify new executive underway Kitty Whitaker Kitty Whitaker, retiring CEO of By the Bay HealthLARKSPUR, Calif., Feb. 06,...
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global...
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy
NEW ORLEANS and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused...
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress
Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” highlights data generated...
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims...
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma”...
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing...
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination...
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the...
ORYZON to Give Updates on Corporate Progress in February-March
BIO CEO & Investor Conference 2023IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer...